Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is to investigate whether neoadjuvant chemotherapy plus SBRT results in better
outcomes compared with neoadjuvant chemotherapy alone and also compare the efficacy of
gemcitabine plus nab-paclitaxel with SBRT and S-1 plus nab-paclitaxel with SBRT.